Founded in 2005, True Ventures is a Silicon Valley-based venture capital firm that invests in early-stage technology startups. With more than $3.8 billion under management, True provides seed and Series A financing to entrepreneurs in some of today's growing markets.  With more than 40 team members including special advisors, operations professionals, and founders-turned-investors, True represents one of the largest and most experienced teams dedicated to the ecosystem.  The True team believes creativity flourishes when founders are supported fully and empowered to pursue brave ideas. To that end, the True Platform offers programs that inspire professional and personal growth. To date, True has helped more than 350 companies launch and scale their businesses, creating over 85,000 jobs worldwide.  True was awarded Venture Firm of the Year by the National Venture Capital Association in 2018. To learn more, visit www.trueventures.com.

True Ventures

Wireframe Ventures is a venture capital firm investing at the seed and pre-seed stage. We back missionary founders using technology to positively impact people & planet.

Wireframe Ventures

Village Global is an early stage venture capital firm backed by some of the world's most successful entrepreneurs.

Village Global

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investment strategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Lux Capital

Two Sigma Ventures is an early-stage venture capital fund based in New York City investing capital and expertise in entrepreneurs leveraging data and computing to create the future. In partnership with our parent company, Two Sigma Investments, we provide entrepreneurs access to a proprietary network of experts and startup resources to give them a competitive edge.

Two Sigma Ventures

Hummingbird Ventures is a venture capital partner for outlier founders building generational companies. Hummingbird teamed up with many transformative companies, including Kraken, Peak Games, Deliveroo, BillionToOne, Showpad, OneCard, Pristyn Care, Gram Games and many others.

Hummingbird Ventures

Lifeforce Capital invests in digital health companies enabling new care delivery models or more efficient therapeutic development. Lifeforce Capital is headquartered in San Francisco, California.

Lifeforce Capital

Bioverge is a venture capital firm specializing in emerging healthcare startups. The firm operates an investment platform that aims to democratize access to startups solving healthcare’s biggest challenges and accelerating their progress.

Bioverge

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies. It was created by George Petrocheilos and Dr. Jacob Vogelstein in 2020.

Catalio Capital Management

Kinnevik is an industry-focused investment company with an entrepreneurial spirit. Its purpose is to build digital consumer businesses that provide more and better choices. The company does this by working in partnership with talented founders and management teams to create, invest in, and lead fast-growing businesses in developed and emerging markets. Kinnevik believes in delivering both shareholder and social value by building well-governed companies that contribute positively to society.  Kinnevik was founded in 1936 by the Stenbeck, Klingspor, and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm's list for large-cap companies under the ticker codes KINV A and KINV B.

Kinnevik

FPV Ventures is a venture capital investment firm.

FPV Ventures

Dimension is a venture capital firm that prefers to invest in biotech,life science, software, infrastructure, lab tools and instruments, clinical development, manufacturing commercialization, machine learning, and artificial intelligence industries.

Dimension Capital

Allen & Company is a family-owned investment and advisory firm. The firm advises on M&A and capital raises, with an emphasis on the technology, media, healthcare, and sports sectors. Allen & Company was established in 1932 and is headquartered in New York, United States.

Allen & Company

JAZZ Venture Partners is the leading venture capital firm focused on technologies that extend the boundaries of human performance. They invest in companies at the intersection of digital technology and neuroscience. They are interested in companies that leverage cutting-edge brain science to inform powerful technology platforms that are impacting the human experience, such as virtual and augmented reality, immersive video gaming, artificial intelligence, and closed-loop human-computer systems. Their portfolio companies are unlocking human potential in important markets: health, mind-body wellness, peak mental and physical performance, accelerated learning and training, sports, and entertainment.  The partners are proven investors, entrepreneurs, neuroscientists, and technologists. They have deep domain experience and unparalleled access to innovative companies, talent, and strategic resources. Their multidisciplinary backgrounds allow us to meaningfully support exceptional entrepreneurs and executives in building category-defining companies.

Jazz Venture Partners

Level.VC invests in disruptive startups in Silicon Valley, NYC, and Israel that are directly developing machine learning, robot learning, and computer vision-powered solutions or are developing products & services powered by these technologies.

Level Ventures

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.

Amino Collective

Possible Ventures backs ambitious teams building frontier technology to positively impact people and the planet. We invest in the early stages, actively supporting founders via our collective of global entrepreneurs. We're unabashed optimists when it comes to the power of technology to solve problems. And we invest our time and capital to help make innovation possible. We’re excited by technology ecosystems that are changing our future: the combination of AI, robotics and satellites that helps build new climate solutions and food systems; the convergence of blockchain and cryptocurrencies making decentralised finance possible; and new technologies like machine learning, genetic modification and synthetic biology that are enabling human health breakthroughs. We've harnessed the experience and networks of a global collective of entrepreneurs. Together, we discover and support great companies aligned with our mission. This armada of angels gives time and capital to 'pay it forward' to the next generation of founders in pursuit of a better world. We started this mission as Inventures. Our name has changed, but our collective approach and microfund strategy remain the same. We're redefining what's Possible.

Possible Ventures

Nature Conservancy works toward achieving its goal of conserving lands and waters through the dedicated efforts of their diverse staff, including more than 600 scientists, located in all 50 U.S. states and more than 35 countries, with the help of many partners, from individuals and governments to local nonprofits and corporations by using a non-confrontational, collaborative approach.

The Nature Conservancy

PremjiInvest is a multi-family office specializing in private equity and venture capital investments. It is a private equity fund owned by Azim Premji which manages his $1 billion personal portfolios. In 2011, Azim Premji invested around $15 million in Vinod Khosla's clean-tech fund.

PremjiInvest

Microsoft is an American multinational corporation that develops, manufactures, licenses, supports, and sells a range of software products and services. Microsoft’s devices and consumer (D&C) licensing segment licenses the Windows operating system and related software, Microsoft Office for consumers, and the Windows Phone operating system. The company’s computing and gaming hardware segment provides Xbox gaming and entertainment consoles and accessories, second-party and third-party video games, and Xbox Live subscriptions; surface devices and accessories; and Microsoft PC accessories. Its phone hardware segment offers Lumia smartphones and other non-Lumia phones. Its D&C segment provides Windows Store, Xbox Live transactions, and Windows phone store; search advertising; display advertising; Office 365 Home and Office 365 Personal; first-party video games; and other consumer products and services as well as operating retail stores. Microsoft’s commercial licensing segments license server products, including Windows Server, Microsoft SQL Server, Visual Studio, System Center, and related Client Access Licenses (CALs); Windows Embedded; Windows operating system; Microsoft Office for business, including Office, Exchange, SharePoint, Lync, and related CALs; Microsoft Dynamics business solutions; and Skype. Its commercial segment offers enterprise services, including premier support services and Microsoft consulting services; commercial cloud comprising Office 365 Commercial, other Microsoft Office online offerings, Dynamics CRM Online, and Microsoft Azure; and other commercial products and online services. The company markets and distributes its products through original equipment manufacturers, distributors, and resellers, as well as online.

Microsoft

Lingotto is an investment management company owned by Exor N.V. and launched by the Italian dynasty the Agnelli family. The company possesses a set of distinctive competitive edges that distinguish it in the market. One key strength lies in its unique investment strategies, which are complementary, differentiated, and unparalleled, providing a competitive advantage over its peers. Moreover, the company has fostered a culture of partnership, promoting autonomy and cooperation among its stakeholders. This collaborative approach not only enhances teamwork but also strengthens relationships within the organization. Another significant aspect of the company's operations is its unwavering commitment to accountability, integrity, and transparency, ensuring a high level of trust and reliability for its clients and partners.

Lingotto

Baillie Gifford is an independently owned investment management firm. It is owned and run by 39 of its senior executives, who operate as a partnership, a structure that has endured for over a century and provides stability for clients and motivation for employees. It enables them to manage the business for the future as well as the present, with an emphasis on genuine long-term thinking rather than lurching haplessly between short-term targets.

Baillie Gifford

Dimension Capital Management is an independent wealth management firm.

Dimension Capital Management

Cresset Partners

Enveda Biosciences

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from living organisms. By developing a comprehensive database of chemical biodiversity, Enveda aims to accelerate the discovery of new medicines.

Enveda Biosciences is a biotechnology company focused on transforming natural products into novel therapeutics using advanced technologies. Enveda leverages its platform combining metabolomics, ML, and high-throughput experiments to explore the chemical diversity of the natural world. This approach enables the company to rapidly identify and develop new drug candidates. The platform, which according to the company includes the world's largest computable database of ethnobotany, allows it to map chemical structures, biological activities, and organ distribution of small molecules in order to accelerate the drug discovery process.​

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Enveda raises USD 130 million in Series C funding to advance AI pipeline.. Enveda Biosciences.. product 

Azure

To leverage Microsoft Azure's compute resources and develop PRISM, a foundation model trained on the world's largest collection of experimental mass spectra, to accelerate Enveda's natural product drug discovery platform.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

NVIDIA

Enveda Biosciences is a biotechnology company focused on transforming natural products into novel therapeutics using advanced technologies. Enveda leverages its platform combining metabolomics, ML, and high-throughput experiments to explore the chemical diversity of the natural world. This approach enables the company to rapidly identify and develop new drug candidates. The platform, which according to the company includes the world's largest computable database of ethnobotany, allows it to map chemical structures, biological activities, and organ distribution of small molecules in order to accelerate the drug discovery process.​Key customers and partnershipsEnveda Biosciences has formed strategic partnerships with several key players in the pharmaceutical and biotechnology sectors to bolster its drug discovery efforts. Notable partnerships include that with Microsoft in <a href="https://www.businesswire.com/news/home/20240529298878/en/Enveda-Biosciences-Announces-Microsoft-Collaboration-and-Reveals-Foundation-Model-to-%E2%80%9CRead-and-Translate%E2%80%9D-Chemistry">May 2024</a> to work on creating a new foundation model, called PRISM, trained on a large collection of experimental mass spectra.In June 2024, the company partnered with <a href="https://sp-edge.com/updates/29873">Microsoft</a> to develop its foundation model, "PRISM." The partnership gave Enveda access to Microsoft Azure's computing resources for scaling its AI models.&nbsp;

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

ANALYST_QUICK_TAKE

<div>
 
 An artificial intelligence (AI) driven biotechnology company, Enveda, has successfully garnered a solid amount of USD 130 million through its Series C funding round. The funding round was led by Kinnevik and FPV, and saw participation from several other investors including Baillie Gifford, Premji Invest, and Lingotto Innovation. The total amount that the company has raised now totals to a whopping USD 360 million.
 The capital raised from this funding round will be primarily invested in developing various programs that have the potential to be commercialized in the years 2025 and 2026. The company also has devised a plan to further advance its AI pipeline of 10 development candidates in addition to several other discovery programs.
 
</div> Analyst QuickTake: 
 Enveda Biosciences recently closed its Series B funding round; the latest Series B-2 round closed in <a href="https: 
//sp-edge.com/updates/30502"> June 2024 </a> . The funds were directed toward AI pipeline development, with plans to commence Phase I clinical trials for its three lead programs in late 2024 and early 2025. Its lead candidate, ENV-294 for atopic dermatitis, commenced Phase I clinical trials in <a href="https: 
//finance.yahoo.com/news/enveda-announces-first-candidate-discovered-120000067.html?utm_source=chatgpt.com#: 
~: 
text=The%20company%20also%20announced%20it%20has%20entered%20this%20candidate%2C%20named%20ENV%2D294%2C%20into%20a%20Phase%20I%20clinical%20trial%2C%20with%20the%20first%20patient%20dosed%20at%20the%20end%20of%20October"> October 2024 </a> .

Enveda Biosciences

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless